Potent antitumor activity of ensartinib in MET exon 14 skipping-mutated non-small cell lung cancer-Reference-Cited by-同舟云学术

Potent antitumor activity of ensartinib in MET exon 14 skipping-mutated non-small cell lung cancer

Published:2023-05 Issue: Volume:561 Page:216140
ISSN:0304-3835
Container-title:Cancer Letters
language:en
Short-container-title:Cancer Letters

Author:

Xia Yang^ORCID,Jin Rui,Li Miao,Lan Fen,Zhu Hao,Yu Yinghui,Miao Da,Wang Qiyuan,Zhou Yi,Selvaggi Giovanni,Ying Songmin,Zhang Jianjun,Shen Huahao,Le Xiuning,Li Wen

Funder

Wuhan University School of Medicine

Betta Pharmaceuticals

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference30 articles.

1. Changing the therapeutic landscape in non-small cell lung cancers: the evolution of comprehensive molecular profiling improves access to therapy;Sabari;Curr. Oncol. Rep.,2017

2. Prevalence and clinical association of MET gene overexpression and amplification in patients with NSCLC: results from the European Thoracic Oncology Platform (ETOP) Lungscape project;Bubendorf;Lung Cancer,2017

3. MET amplification and exon 14 splice site mutation define unique molecular subgroups of non-small cell lung carcinoma with poor prognosis;Tong;Clin. Cancer Res.,2016

4. Characterization of 298 patients with lung cancer harboring MET exon 14 skipping alterations;Schrock;J. Thorac. Oncol.,2016

5. MET exon 14 mutations in non-small-cell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and c-met overexpression;Awad;J. Clin. Oncol.,2016

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Savolitinib conferred sensitivity in a patient with D1228H mutation-induced capmatinib-resistant MET exon 14 skipping mutated lung adenocarcinoma;Journal of Cancer Research and Clinical Oncology;2024-08-24

2. LILRB2 inhibition enhances radiation sensitivity in non-small cell lung cancer by attenuating radiation-induced senescence;Cancer Letters;2024-07

3. NONO promotes gallbladder cancer cell proliferation by enhancing oncogenic RNA splicing of DLG1 through interaction with IGF2BP3/RBM14;Cancer Letters;2024-04

4. The MET Oncogene: Thirty Years of Insights into Molecular Mechanisms Driving Malignancy;Pharmaceuticals;2024-03-30

5. Targeting MET in NSCLC: An Ever-Expanding Territory;JTO Clinical and Research Reports;2024-02